Net Product Sales by Geographic Region and Product Line, and Composition of License Fees and Service Revenue

6 Months Ended

Jun. 30, 2016

Segment Reporting [Abstract]

Net Product Sales by Geographic Region and Product Line, and Composition of License Fees and Service Revenue

NET PRODUCT SALES BY GEOGRAPHIC REGION AND PRODUCT LINE, AND COMPOSITION OF LICENSE FEES AND SERVICE REVENUE

The below table presents our net product sales by geography for the three and six months ended June 30, 2016 and 2015:

	Three Months Ended June 30,								Six Months Ended June 30,
	2016				2015				2016				2015
United States	$	30,037	97.2	%	$	33,676	95.8	%	$	63,816	96.5	%	$	70,284	95.6	%
International:
Europe	850		2.8	%	514		1.5	%	2,313		3.5	%	1,097		1.5	%
Asia Pacific*	—		—	%	954		2.7	%	—		—	%	2,176		3.0	%
Total international	850		2.8	%	1,468		4.2	%	2,313		3.5	%	3,273		4.5	%
Net product sales	$	30,887	100.0	%	$	35,144	100.0	%	$	66,129	100.0	%	$	73,557	100.0	%

* See Note 11 for discussion of our November 2015 out-license for Asia Pacific territory to Mundipharma.

The below table presents our net product sales by product line for the three and six months ended June 30, 2016 and 2015:

	Three Months Ended June 30,								Six Months Ended June 30,
	2016				2015				2016				2015
FUSILEV	$	10,467	33.9	%	$	14,329	40.8	%	$	25,676	38.8	%	$	34,496	46.9	%
FOLOTYN	10,970		35.5	%	12,222		34.8	%	24,262		36.7	%	21,538		29.3	%
ZEVALIN	2,811		9.1	%	4,802		13.7	%	5,595		8.5	%	9,023		12.3	%
MARQIBO	2,067		6.7	%	2,080		5.9	%	2,996		4.5	%	3,974		5.4	%
BELEODAQ	3,664		11.9	%	1,711		4.9	%	6,692		10.1	%	4,526		6.2	%
EVOMELA	908		2.9	%	—		—	%	908		1.4	%	—		—	%
Net product sales	$	30,887	100.0	%	$	35,144	100.0	%	$	66,129	100.0	%	$	73,557	100.0	%

The below table presents our license fee and service revenue by source for the three and six months ended June 30, 2016 and 2015:

	Three Months Ended June 30,								Six Months Ended June 30,
	2016				2015				2016				2015
Out-license to Servier in Canada territory (Note 12)	$	—	—	%	$	—	—	%	$	6,000	51.3	%	$	—	—	%
Co-Promotion with Eagle (Note 13)	2,398		78.3	%	—		—	%	4,332		37.1	%	—		—	%
Out-license to Mundipharma in China and other ex-U.S. territories (Note 11 and 15)	629		20.5	%	144		1.5	%	1,313		11.2	%	336		3.3	%
Out-license to CASI in China territory (Note 10)	—		—	%	9,682		98.4	%	—		—	%	9,682		96.4	%
Other license fees and service revenues	35		1.1	%	12		0.1	%	41		0.4	%	24		0.2	%
License fees and service revenues	$	3,062	100.0	%	$	9,838	100.0	%	$	11,686	100.0	%	$	10,042	100.0	%